News
NVSEF
161.50
NaN%
--
Trump says tariffs prompt Novartis to expand U.S. manufacturing
Seeking Alpha · 1d ago
Novartis inks licensing deal worth up to $1.8B for oral peptide drugs
Seeking Alpha · 3d ago
Weekly Report: what happened at NVSEF last week (0209-0213)?
Weekly Report · 5d ago
GMOI: This International ETF Is Off To A Strong Start
Seeking Alpha · 02/12 21:01
Bristol-Myers: Walking Blindfolded To A $30 Billion Patent Cliff
Seeking Alpha · 02/11 15:00
AVDE: Diversified And Effective Active ETF At A Low Cost
Seeking Alpha · 02/10 17:39
Oakmark International Strategy adds Unilever, Sanofi in Q4, exits Novartis
Seeking Alpha · 02/10 14:33
Weekly Report: what happened at NVSEF last week (0202-0206)?
Weekly Report · 02/09 09:30
Novartis proposes dividend raise to CHF 3.70
Seeking Alpha · 02/04 06:24
Novartis reports mixed Q4 results; initates FY26 soft outlook
Seeking Alpha · 02/04 06:05
Weekly Report: what happened at NVSEF last week (0126-0130)?
Weekly Report · 02/02 09:29
IBB: Beyond The 2025 Surge, Biotech Breakout
Seeking Alpha · 01/27 10:10
Weekly Report: what happened at NVSEF last week (0119-0123)?
Weekly Report · 01/26 09:29
Novartis: Upside Increasingly Capped, 2026 Will Be A Transition Year (Rating Downgrade)
Seeking Alpha · 01/25 13:31
RAPT Therapeutics: A Buy As GSK Acquisition Highlights Long-Acting IgE Candidate
Seeking Alpha · 01/20 20:15
Weekly Report: what happened at NVSEF last week (0112-0116)?
Weekly Report · 01/19 09:32
Novartis wins FDA breakthrough status for Sjögren’s disease therapy
Seeking Alpha · 01/16 17:28
Weekly Report: what happened at NVSEF last week (0105-0109)?
Weekly Report · 01/12 09:31
Weekly Report: what happened at NVSEF last week (1229-0102)?
Weekly Report · 01/05 09:30
2026 S&P 500 Outlook: Look For Pharma Sector To Lead The Way With Potential Changes
Seeking Alpha · 12/29/2025 14:20
More
Webull provides a variety of real-time NVSEF stock news. You can receive the latest news about Novartis through multiple platforms. This information may help you make smarter investment decisions.
About NVSEF
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.